Previous 10 | Next 10 |
2023-03-21 08:13:14 ET Summary TERN has a growing pipeline of early-stage assets against validated targets. TERN's internal discovery team has been productive at developing small molecules against key targets in big markets. TERN has an important NASH readout coming in Q3 23. ...
2023-03-17 18:18:37 ET Summary As pegozafermin has a differentiated mode of action from Madrigal's resmetirom, 89bio, Inc. can offer an intriguing solution for NASH. Early pegozafermin data showed extremely strong liver fat reduction as well as improvement in NASH. The upcomin...
2023-03-16 14:43:48 ET Summary Biotech name Viking Therapeutics is going back into the spotlight for the first time in nearly a year in today's focus article. Thanks mainly to promising results from a competitor in the NASH space, the shares have soared more than 150% since Decemb...
2023-03-10 09:23:14 ET The FDA announced on Friday that a group of independent experts would meet in May to discuss the marketing application for Obeticholic Acid (OCA), a liver disease candidate developed by Intercept Pharmaceuticals ( NASDAQ: ICPT ) for nonalcoholic steatohepa...
Healthcare stocks were a mixed bag in 2022. While healthcare giants that pay dividends to shareholders churned higher as a result of their inherent safety, pure-play research and developmental companies, on balance, lost significant ground from a valuation standpoint last year. Investors so...
Madrigal Pharmaceuticals press release ( NASDAQ: MDGL ): Q4 GAAP EPS of -$4.98 misses by $0.48 . As of December 31, 2022, Madrigal had cash, cash equivalents and marketable securities of $358.8 million, compared to $270.3 million at December 31, 2021. The increase in cash ...
Positive Phase 3 MAESTRO-NASH study results reported in December 2022 position Madrigal for a resmetirom new drug application filing in the first half of 2023 Madrigal reports year end cash, cash equivalents and marketable securities of $358.8M CONSHOHOCKEN, Pa., Feb. 23, 2023 (GL...
Summary Bumbershoot Holdings uses a fundamental investment strategy as a “quality over quantity” approach to identifying and evaluating great businesses. It primarily invests in small- and mid- capitalization public companies. Bumbershoot Holdings registered a gain of +1.2...
Summary Biotech stocks have pulled back and offer better risk to reward for investors, Direxion Daily S&P Biotech Bull 3x Shares ETF is a popular way to trade them. M&A is likely to drive prices for mid-cap and small-cap biopharma. Using a leveraged ETF like LABU is risky, e...
Summary Healthcare significantly outperformed the broader market last year, after two years of underperforming the S&P 500. When the end to restrictive policy is in sight, then the sector is likely to witness a group rotation to more growth-oriented stocks. Groups like medical d...
News, Short Squeeze, Breakout and More Instantly...
Madrigal Pharmaceuticals Inc. Company Name:
MDGL Stock Symbol:
NASDAQ Market:
Madrigal Pharmaceuticals Inc. Website:
CONSHOHOCKEN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2024 financial results on Wednesday, August 7, 2024, prior to the open of the U.S. financial markets. Following the announcement...
2024-06-30 12:02:00 ET Madrigal Pharmaceuticals (NASDAQ: MDGL) is at a moment of great opportunity, and there's a decent chance that its shareholders will feel good about their investments over the next few years. After commercializing its first medicine, which treats a condition no...
2024-06-16 12:05:00 ET If you're eyeing an investment in Madrigal Pharmaceuticals (NASDAQ: MDGL) , now's the time to imagine a representative of Eli Lilly (NYSE: LLY) interrupting your train of thought by saying something along the lines of, "Not so fast." While the biotech ...